☆ 4.7 Editorial Material

Cefiderocol for the Treatment of Metallo-β-Lactamases Producing Gram-Negative Bacilli: Lights and Shadows From the Literature

CLINICAL INFECTIOUS DISEASES (2022)

Related references

Note: Only part of the references are listed.

Article Immunology

Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy is Associated With an Increase in blaNDM-5 Copy Number and Gene Expression

Patricia J. Simner et al.

Summary: This study revealed the mechanisms by which New Delhi metallo-β-lactamase-producing Escherichia coli isolate developed relatively rapid resistance to cefiderocol through increased copy numbers of bla(NDM) genes. The findings highlight the importance of investigating increased bla(NDM-5) expression frequency in contributing to cefiderocol resistance.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Immunology

Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies

Jean-Francois Timsit et al.

Summary: The CREDIBLE-CR and APEKS-NP studies showed that cefiderocol treatment is effective against gram-negative bacteria producing metallo-B-lactamases, with favorable rates of clinical cure, microbiological eradication, and all-cause mortality compared to other treatment options.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Microbiology

Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii

Marco Falcone et al.

Summary: Cefiderocol appears to be a promising therapeutic option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections, with a potential protective effect on 30-day mortality. However, further studies are needed to address the issue of microbiological failure.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Add to Collection

Article Infectious Diseases

The urgent need for metallo-β-lactamase inhibitors: an unattended global threat

Maria F. Mojica et al.

Summary: Beta-lactams are the most potent class of antibiotics in clinical use due to their superior tolerability and efficacy. However, resistance to these antibiotics, particularly due to beta-lactamases, remains a challenge. The limited effectiveness of beta-lactamase inhibitors against metallo-beta-lactamases and the potential exacerbation of antimicrobial resistance due to increased antibiotic use in COVID-19 patients are key concerns.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Immunology

Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales

Marco Falcone et al.

Summary: This study aimed to compare the outcomes of patients with MBL-producing Enterobacterales bloodstream infections treated with CAZ-AVI + ATM or other active antibiotics. The results showed that CAZ-AVI + ATM was associated with lower 30-day mortality, lower clinical failure at day 14, and shorter length of stay.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients

Marco Falcone et al.

Summary: In this study, cefiderocol was used to treat patients with bacteremia or ventilator-associated pneumonia caused by drug-resistant strains, showing a 70% clinical success rate and 90% survival rate. However, two patients experienced microbiological failure, highlighting the need for future prospective studies to further evaluate the effectiveness of the treatment.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study

Marco Falcone et al.

Summary: Superinfections with bacteria and fungi are common in hospitalized patients with COVID-19, especially in those receiving empirical broad-spectrum antibiotics and immunomodulatory drugs. Infection control measures need to be reinforced to prevent and manage superinfections effectively.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

Add to Collection

Article Infectious Diseases

Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens

Jacob E Choby et al.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia

Takayuki Katsube et al.

Summary: This study assessed the intrapulmonary pharmacokinetic profile of cefiderocol in hospitalized, mechanically ventilated pneumonia patients, showing that cefiderocol can penetrate the epithelial lining fluid in the lungs with concentrations sufficient to treat Gram-negative bacteria.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

Add to Collection

Article Infectious Diseases

Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study

Renato Pascale et al.

Summary: This study confirms the potential role of cefiderocol in the treatment of CR-Ab infection, but larger clinical studies are needed for further validation.

JAC-ANTIMICROBIAL RESISTANCE (2021)

Add to Collection

Article Infectious Diseases

Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study

Renato Pascale et al.

Summary: This study analyzed the impact of cefiderocol use on patients with severe COVID-19 admitted to the ICU and further diagnosed with carbapenem-resistant Acinetobacter baumannii (CR-Ab) infection. The results suggest that cefiderocol may have a potential role in the treatment of CR-Ab infection, but larger clinical studies are needed for confirmation.

JAC-ANTIMICROBIAL RESISTANCE (2021)

Add to Collection

Article Infectious Diseases

Prolonged outbreak of New Delhi metallo-beta-lactamase-producing carbapenem-resistant Enterobacterales (NDM-CRE), Tuscany, Italy, 2018 to 2019

Lara Tavoschi et al.

EUROSURVEILLANCE (2020)

Add to Collection

Article Immunology

Clinical Features and Outcomes of Bloodstream Infections Caused by New Delhi Metallo-β-Lactamase-Producing Enterobacterales During a Regional Outbreak

Marco Falcone et al.

OPEN FORUM INFECTIOUS DISEASES (2020)

Add to Collection

Article Microbiology

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria

Shazad Mushtaq et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

Add to Collection

Article Infectious Diseases

In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe

Christopher Longshaw et al.

JAC-ANTIMICROBIAL RESISTANCE (2020)

Add to Collection

Review Immunology

Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations

David van Duin et al.

CLINICAL INFECTIOUS DISEASES (2016)

Add to Collection

© Peeref 2019-2024. All rights reserved.